NATCO PHARMA LTD. SHARE PRICE [LIVE]

BSE: INE987B01026   NSE: NATCOPHARM   SECTOR: Pharma

OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
647.30
Change:
BSE
646.00
Change:
NSE
BSE Click here to view BSE data
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality
Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
Sector
Sensex
Name Mar 21 Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in NATCO PHARMA LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

NATCOPHARM News

Frequently Asked Questions

What is the Share price of NATCO PHARMA LTD. (NATCOPHARM)?

NATCO PHARMA LTD. (NATCOPHARM) share price as of August 19, 2022, on NSE is Rs 647.30 (NSE) and Rs 646.00 (BSE) on BSE.

Can I buy NATCO PHARMA LTD. (NATCOPHARM) shares?

Yes, You can buy NATCO PHARMA LTD. (NATCOPHARM) shares by opening a Demat account with Angel One.

How do I buy NATCO PHARMA LTD. (NATCOPHARM) from Angel One?

NATCO PHARMA LTD. (NATCOPHARM) share can be brought through the following modes:
  1. Direct investment: You can buy NATCO PHARMA LTD. (NATCOPHARM) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to NATCO PHARMA LTD. (NATCOPHARM) shares.

In which sector do NATCO PHARMA LTD. (NATCOPHARM) belong?

NATCO PHARMA LTD. (NATCOPHARM) belongs to Pharma.

About NATCOPHARM

Today's live share price for NATCO PHARMA LTD. is NSE: ₹ 647.30, BSE: ₹ 646.00 with a current market capitalization of .

Incorporated in Sep.'81 as Natco Fine Pharmaceutical Ltd, it became a deemed public company with effect from Jul.'92 and in Feb.'93, it changed its name to Natco Pharma (NPL). NPL began to manufacture conventional and time-release dosage forms of life-saving drugs. NPL is a contract manufacturer for reputed companies like Ranbaxy and Parke Davis. It has also obtained the coveted ISO 9002 certification, which will boost exports. It has initiated registration proceedings (for its formulations) in over 20 countries. To channelise its operations in the US, NPL has formed a new subsidiary, Natco Pharma, US. It has entered into research collaborations with Regional Research Laboratories, Jammu, for keto-L-gluconic acid (a penultimate for iso-ascorbic acid), with the Centre for Cellular & Molecular Biology for synthetic peptides and with the Central Leather Research Institute for oral vaccines. The company has introduced drugs like diltiazem, mononitrate, etc, in time-release form. Natco Laboratories, Natco Parenterals and Karanth Pharmaceuticals have merged with the flagship company, NPL to capitalise on the opportunities in the post-GATT era, to provide a large asset base and to increase high-technology capability. During 1995-96, NPL has implemented the project for formulations in the US. As a part of its diversification plans, the company is participating in the development of Krishnapatnam Industrial Port City Project, Nellore District, in collaboration with ITOCHU, Japan; Flour Daniels, USA; and HAM, Netherlands to create infrastructure. During 1996-97, the company entered into a agreement whereby Ranbaxy Laboratories (RLL) acquires rights in marketing certain NPL's products in Russia, Ukraine and other countries of CIS. Krishnapatnam Port Project has succeeded in signinig up with the UK based Indo British Port Development Consortium to develop the project. Natco is a minority participant in this project. The Andhra Pradesh government has extended the time allowed for time closure of Krishnapatnam Port project by another 2 years. The project is now proposed to be developed in 2 phases. In the first phase,it proposed to contrct 2 berths-one for loading and another for unloading. This facility is expected to be operational by August/September,2002 and thereafter,lighterage operations could commence.

Read more